Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre

E. N'Kaoua (1) , S. Attarian (2) , E. Delmont (1) , Emmanuelle Salort-Campana (2, 3) , A. Verschueren (1) , A-M Grapperon (1) , E. Mestivier (1) , M. Roche (1)

1 APHM - Assistance Publique - Hôpitaux de Marseille
2 MMG - Marseille medical genetics - Centre de génétique médicale de Marseille
3 TIMONE - Hôpital de la Timone [CHU - APHM]

Background Growing numbers of indications for intravenous immunoglobulins (IVIg) in recent years has resulted in an increase in the consumption of these products. A lack of raw material has led to IVIg shortage. The objective of this work was to evaluate the impact of this situation on patient care in one French referral centre considering practice modifications and clinical impact. Methods All patients treated with IVIg for chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and myasthenia gravis from October 2017 to October 2018 were included. Results Out of 142 patients, 111 (78%) had a modification of their IVIg treatment. We noted that 75 (68%) patients had a delay in IVIg treatment, 41 (37%) patients had a decrease in IVIg doses and 31 (28%) experienced IVIg treatment interruption. Thirty percent of patients for whom IVIg treatment was discontinued were switched to other treatments mainly plasma exchange (16%) or corticosteroids (13%). Switches to plasma exchange or corticosteroids were carried out in order to save immunoglobulins for patients who had no other alternatives. Fifty-eight (52%) patients presented a deterioration of their clinical score after IVIg treatment changes including 31 (28%) patients who had a moderate or a clinically significant deterioration. Concerning practice modifications, we noted a substantial though not significant decrease in median IVIg dose for myasthenia gravis and a significant increase in the delay between IVIg courses for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy (P = 0.011 and P = 0.018 respectively). Conclusion Our study showed a rather important number of changes in IVIg treatment related to IVIg shortage during the period considered. These changes had a negative impact on the clinical status of some patients.

Domaines: Génétique

E. N'Kaoua, S. Attarian, E. Delmont, Emmanuelle Salort-Campana, A. Verschueren, et al.. Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre. Revue Neurologique, 2022, 178 (6), pp.616-623. ⟨10.1016/j.neurol.2021.10.004⟩. ⟨hal-03780345⟩